Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course

被引:65
作者
Miller, Elzbieta [1 ,2 ]
Walczak, Anna [3 ]
Majsterek, Ireneusz [3 ]
Kedziora, Jozef [4 ]
机构
[1] Med Univ Lodz, Dept Phys Med, PL-94124 Lodz, Poland
[2] III Gen Hosp Lodz, Neurorehabil Ward, Lodz, Poland
[3] Med Univ Lodz, Dept Chem & Clin Biochem, PL-94124 Lodz, Poland
[4] Nicholas Copernicus Univ, Chair & Dept Biochem, Coll Med Bydgoszcz, Torun, Poland
关键词
Melatonin; Oxidative stress; Multiple sclerosis; DISABILITY STATUS; AUTOXIDATION; STROKE; BRAIN; MICE;
D O I
10.1016/j.jneuroim.2013.02.012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Oxidative stress plays a major role in multiple sclerosis (MS). melatonin is a potent neuroprotectant. The aims of this study were to determine the actions of melatonin in the reduction of oxidative stress in MS. Therefore, we estimated lipid peroxidation and activities of main antioxidative enzymes in the red blood cells (RBCs) from selective group of MS patients only with secondary progressive (SPMS) clinical form and verified results with functional state. The sixteen (n = 16) SPMS patients were supplemented with melatonin (10 mg daily/30 days). Age matched healthy subjects were used as a control (n = 13). We determined the level of lipid peroxidation by malondialdehyde (MDA) and activities of main antioxidative enzymes: superoxide dismutase (SOD), catalase (CAT) and glutathione peroxide (GPx) in RBCs of SPMS patients. Melatonin caused statistically significant increase of SOD, GPx (p < 0.0001 and p = 0.004065, respectively) and decrease of MDA in erythrocytes of SPMS patients (p = 0.00019). Correlation analysis of Spearman showed positive correlation between SOD and (expanded disability status scale) EDSS scale both before (r = 0.64, p = 0.00756) and after (r = 0.634, p = 0.00834) melatonin treatment. These results demonstrate that supplementation with melatonin SPMS patients should be taken into account, especially in progressive form of MS. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:97 / 101
页数:5
相关论文
共 50 条
[41]   Patients’ Experiences in Transitioning to Secondary Progressive Multiple Sclerosis: Qualitative Interviews [J].
Sandy Lewis ;
Sibyl E. Wray ;
Emily Evans ;
Carla Romano ;
Lauren Bartolome ;
Wendy Su ;
Roshani Shah ;
Patricia A. Russo .
Neurology and Therapy, 2021, 10 :887-904
[42]   Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis [J].
Kern, Simone ;
Geiger, Michael ;
Paucke, Madlen ;
Kaestner, Alina ;
Akguen, Katja ;
Ziemssen, Tjalf .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2019, 97 (11) :1547-1555
[43]   Disability in patients with multiple sclerosis: Influence of insulin resistance, adiposity, and oxidative stress [J].
Oliveira, Sayonara Rangel ;
Colado Simao, Andrea Name ;
Kallaur, Ana Paula ;
Delicato de Almeida, Elaine Regina ;
Morimoto, Helena Kaminami ;
Lopes, Josiane ;
Dichi, Isaias ;
Kaimen-Maciel, Damacio Ramon ;
Vissoci Reiche, Edna Maria .
NUTRITION, 2014, 30 (03) :268-273
[44]   Oxidative stress markers in patients with multiple sclerosis during an outbreak and its remission [J].
Paloma Soto-Brambila, Ada ;
Gabriel Ortiz, Genaro ;
Laura Briones-Torres, Ana ;
Rivero-Moragrega, Paloma ;
Cortes-Romero, Celso ;
Paul Pacheco-Moises, Fermin .
ACTA BIOQUIMICA CLINICA LATINOAMERICANA, 2019, 53 (02) :167-173
[45]   Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial [J].
Cheshmavar, Masoumeh ;
Mirmosayyeb, Omid ;
Badihian, Negin ;
Badihian, Shervin ;
Shaygannejad, Vahid .
ACTA NEUROLOGICA SCANDINAVICA, 2021, 143 (02) :178-187
[46]   Argentinean consensus guidelines on the identification and clinical care of secondary progressive multiple sclerosis [J].
Cristiano, Edgardo ;
Patrucco, Liliana ;
Ysrraelit, Maria C. ;
Alonso, Ricardo ;
Balbuena, Maria E. ;
Ballario, Carlos ;
Barboza, Andres G. ;
Bestoso, Santiago ;
Burgos, Marcos ;
Caceres, Fernando J. ;
Carra, Adriana ;
Camero-Contentti, Edgar ;
Deri, Norma ;
Fernandez-Liguori, Nora ;
Garcea, Orlando ;
Hryb, Javier P. ;
Jacobo, Miguel ;
Kohler, Eduardo ;
Luetic, Geraldine G. ;
Mainella, Carolina ;
Menichini, Maria L. ;
Miguez, Jimena ;
Nofal, Pedro G. ;
Piedrabuena, Raul ;
Rugilo, Carlos ;
Saladino, Maria L. ;
Silva, Berenice A. ;
Silva, Emanuel ;
Sinay, Vladirimo ;
Tavolini, Dario ;
Tkachuk, Veronica A. ;
Villa, Andres ;
Vrech, Carlos ;
Rojas, Juan, I .
REVISTA DE NEUROLOGIA, 2021, 72 (01) :23-32
[47]   Management of Secondary-Progressive Multiple Sclerosis [J].
Gavin Giovannoni .
CNS Drugs, 2004, 18 :653-669
[48]   Secondary Progressive Multiple Sclerosis: Definition and Measurement [J].
Domenico Plantone ;
Floriana De Angelis ;
Anisha Doshi ;
Jeremy Chataway .
CNS Drugs, 2016, 30 :517-526
[49]   Siponimod for the treatment of secondary progressive multiple sclerosis [J].
Dumitrescu, Laura ;
Constantinescu, Cris S. ;
Tanasescu, Radu .
EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (02) :143-150
[50]   Siponimod to treat secondary progressive multiple sclerosis [J].
Gajofatto, A. ;
Turatti, M. .
DRUGS OF TODAY, 2020, 56 (01) :37-46